Correvio resubmits Brinavess (Vernakalant) NDA to FDA for treatment of onset AF
Correvio Pharma announced it has resubmitted a New Drug Application to the FDA seeking approval for Brinavess™ (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation. June 24, 2019